Media.Player

Compositions and Methods for Determining Cancer Stem Cell Self-Renewal Potential

詳細技術說明

Researchers at UC San Diego have developed a method for determining the self-renewal potential of CSCs. This technology involves CSC-specific analysis and quantitation of key players (splice variants of proteins and transcripts) in metabolic pathways that are critical for cell survival and self-renewal. The analysis of the cross-talk within cell survival and self-renewal pathways enables the: Determination of the self-renewal potential of cancer stem cells.Determination of the prognosis or malignant potential of cancer from the CSC.Identification of targets for drugs that lower self-renewal potential.Prediction of the susceptibility of a CSC to drug treatment (inhibition of self-renewal).

*Abstract

Traditional chemotherapy may fail to achieve complete remission of cancers due to resistance of the underlying cancer stem cells (CSCs) to the therapeutic agents. It is now well accepted that to achieve greater efficacy there is a need to specifically target CSCs within a tumor cell population. Furthermore, understanding the self-renewal potential of these CSCs, as well as their susceptibility to drug treatment and the overall malignant potential of the cancer, are essential steps to more successful cancer therapy.

*IP Issue Date

Nov 24, 2015

*Principal Investigation

Name: Annelie Schairer (Abrahamss)

Department:

Name: Kim-Hien Dao

Department:

Name: Ifat Geron

Department:

Name: Daniel Goff

Department:

Name: Catriona Jamieson

Department:

附加資料

Patent Number: US20110059448A1
Application Number: US2010821738A
Inventor: JAMIESON, Catriona H. | SCHAIRER, Annelie | GERON, Ifat | DAO, Kim-Hien
Priority Date: 23 Jun 2009
Priority Number: US20110059448A1
Application Date: 23 Jun 2010
Publication Date: 10 Mar 2011
IPC Current: C12Q000168 | C12Q000102
US Class: 435005 | 435006 | 43500614 | 435029
Assignee Applicant: The Regents of the University of California
Title: COMPOSITIONS AND METHODS FOR DETERMINING CANCER STEM CELL SELF-RENEWAL POTENTIAL
Usefulness: COMPOSITIONS AND METHODS FOR DETERMINING CANCER STEM CELL SELF-RENEWAL POTENTIAL
Summary: The methods are used for determining the self-renewal potential of a CSC through analysis of the cross-talk between cell self-renewal pathways leading to deregulation and enhanced self-renewal of the CSC, or for predicting the drugability (susceptibility to a drug) of a CSC, and/or for predicting the progression of a cancer that corresponds to the CSC; identifying a target for a composition or drug that inhibits the self-renewal potential of a CSC; and determining the prognosis or malignant potential of a cancer (all claimed).
Novelty: Determining the self-renewal potential of a cancer stem cell (CSC) by detecting and quantifying B-cell lymphoma-2 (Bcl-2) family protein or its isoform or a transcript encoding Bcl-2 family protein or its isoform in CSCs

主要類別

生物醫學

細分類別

DNA /基因工程

申請號碼

9194862

其他

State Of Development

Validation experiments confirm cell type and context specific deregulation of apoptosis via deregulated expression in the CSC population. In vivo studies on CSC engraftment validate the therapeutic potential of targeting survival pathways and in vitro studies suggest mechanism of action.

Intellectual Property Info

Pending U.S. patent application 20110059448.

Related Materials

• Abrahamsson A.E. et al., (2009) Glycogen Synthase Kinase 3beta Missplicing Contributes to Leukemia Stem Cell Generation. Proc Natl Acad Sci USA. 106(10):3925-9.
• Jamieson C.H. (2008) Chronic Myeloid Leukemia Stem Cells. Hematology 1:436-42.
• Jamieson C.H.M. et al., (2008) Miscreant myeloproliferative disorder stem cells. Leukemia 22:2011-9.
• Kitada S. et al., (1998) Expression of Apoptosis-Regulating Proteins in Chronic Lymphocytic Leukemia: Correlations with In Vitro and In Vivo Chemo Responses. Blood. 1998 91(9):3379-89.
• See also http://cancer.ucsd.edu/summaries/cjamieson.asp.

Related Technologies

• Biomarker to Enable Eradication of CML Stem Cells

Additional Technologies by these Inventors

• Therapeutic Approach Targeting Malignant Reprogramming in CML Stem Cells

Tech ID/UC Case

22170/2009-187-0

Related Cases

2009-187-0, 2012-155-0

國家/地區

美國